Pune-based Gennova Biopharmaceuticals' Covid-19 vaccine candidate HGCO19, India's first messenger ribonucleic acid (mRNA) platform-based vaccine, will remain stable at 2-8 degrees Celsius, unlike its global peers – BNT162b2 (from Pfizer-BioNTech) and mRNA-1273 (from Moderna) – that require sub-zero temperatures.

Leave a Reply

Your email address will not be published. Required fields are marked *